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This Month in the Journal
This month in the Journal, Martin Richards and Vincent
Macaulay have contributed an editorial, to accompany
a paper by Finnila¨ et al., that reports the largest set of
human mtDNA sequences to date. The editorial de-
scribes the use of mtDNA in studies of human evolution,
from its beginnings in the late 1970s to the present. The
complete mtDNA sequences that are coming out now
give the highest level of phylogenetic resolution possible,
and they suggest that the basic structure of earlier phy-
logenetic networks was generally accurate.
Craniometaphyseal Dysplasia, by Reichenberger et al.
(p. 1321)
The locus for autosomal dominant craniometaphyseal
dysplasia, on chromosome 5p, was limited to 2–3 Mb
by Reichenberger et al., and it was found to contain only
two fully described genes and several expressed sequence
tags. In this skeletal disorder, there is progressive thick-
ening and increased mineral density of the craniofacial
bones. The TRIO gene in the critical region was ex-
cluded as a candidate by direct sequencing of DNA from
affected individuals. The ANK gene, on the other hand,
was mutated in affected individuals from five different
families. ANK is predicted to encode a multipass trans-
membrane protein. Two in-frame deletions and an in-
frame insertion were all found in a putative cytosolic
domain of ANK, between transmembrane domains 8
and 9, and these mutations appear to create a dominant-
negative protein. Functional studies suggest that ANK
is involved in the transport of intracellular pyrophos-
phate into the extracellular bone matrix. These pyro-
phosphate levels are critical for the regulation of bone
mineralization. Therefore, the authors propose that mu-
tations in ANK lead to decreased pyrophosphate levels
in the bone matrix and, subsequently, to the phenotype
of increased mineral density and progressive thickening
of cranial bones.
Mechanism of N-Terminal PAH Missense Mutations,
by Gjetting et al. (p. 1353)
More than 400 different mutations in the PAH gene,
encoding phenylalanine hydroxylase (PAH), have been
associated with hyperphenylalaninemia. PAH converts
L-phenylalanine to L-tyrosine, and reductions in this ac-
tivity cause phenylalanine to build up in the blood. Al-
most all PAH mutations lie outside the region coding
for the active site of the enzyme, and the missense mu-
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tations in other areas of the gene are thought to be lo-
cated at key structural residues and at residues at domain
interfaces. Gjetting et al. find evidence for another cat-
egory of missense mutation in PAH—that is, mutations
that reduce binding of phenylalanine. Two motifs in the
regulatory domain of PAH are conserved in all eukar-
yotic organisms examined, and there appears to be an
overrepresentation of mutations in the residues forming
these motifs. Regulatory domains of PAH containing
naturally occurring mutations in the conserved motifs
were expressed as fusion proteins with maltose-binding
protein. The fusion proteins showed some increased ag-
gregation but, in general, appeared structurally sound
on reducing and native gels. However, the mutations
reduced or eliminated phenylalanine binding to the pro-
tein. The authors suggest that the activity of some forms
of mutated PAH may depend on the concentration of
phenylalanine in the liver, thereby providing a possible
explanation for the discordant genotype-phenotype as-
sociations that are seen with mutations in this domain.
NPC Variant Detection and Mutation Analysis, by Sun
et al. (p. 1361); and NPC1 Mutations, Protein, and
Phenotypes, by Millat et al. (p. 1373)
Niemann-Pick type C disease (NPC) is a lysosomal stor-
age disorder characterized by the accumulation of unes-
terified cholesterol in the lysosomes and late endosomes.
Clinical manifestations of NPC are varied, with a range
of ages at onset, affected organs, and degrees of neu-
rologic impairment. In addition, there are two biochem-
ical variants of the disease, termed “classic” and “var-
iant,” that are based on the degree of impairment in
cellular cholesterol trafficking. Sun et al. have defined a
new diagnostic method for variant NPC, which uses
BODIPY-lactosylceramide (BODIPY-LacCer). Normal
targeting of this fluorescent sphingolipid analog was seen
when it was incubated with skin fibroblasts of the var-
iant phenotype. In contrast, cells with the classical NPC
phenotype showed transport to endosomes/lysosomes
rather than to the Golgi. If the variant cells were prein-
cubated with LDL, localization of BODIPY-LacCer to
the endocytic system increased. Sun et al. tested this flu-
orescence system as a diagnostic method and found that
they could identify variant cells as NPC in 22 of 23 trials
in this system. Mutations in NPC1 correspond to one
complementation group of NPC. To study the different
clinical and biochemical manifestations of NPC, both
Sun et al. and Millat et al. looked for NPC1 mutations
in a series of affected individuals. They identified several
novel mutations, the majority of which were missense
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mutations. The mutations were scattered throughout the
protein but were somewhat concentrated in the luminal
cysteine-rich loop of NPC1. In all but two of the variant
cell lines for which NPC1 mutations were identified, at
least one of the mutations was in the cysteine-rich loop.
Surprisingly, no NPC1 mutations were found in 5 of the
12 variant cell lines discussed in the article by Sun et al.
Each study identified mutations that were associated
with the variant biochemical phenotype; however, the
P1007A mutation that, in the article by Millat et al.,
was identified as associated with only the variant phe-
notype was found, by Sun et al., in a cell line with the
classical phenotype. Furthermore, although the classical
phenotype is ascribed to the I1061T mutation, Millat et
al. find that, in combination with the P1007A mutation,
this mutation gives a variant phenotype. They suggest
that one copy of a variant-associated mutation is suffi-
cient for expression of the variant phenotype, even if the
second mutation has been associated with the classical
phenotype. As more NPC1 mutations are identified,
these genotype-phenotype correlations should certainly
become better defined.
New, Prevalent Mutation That Results in MCAD
Deficiency, by Andresen et al. (p. 1408)
In populations of European descent, there is a high car-
rier frequency of a mutation, 985ArG, in the gene for
medium-chain acyl-CoA dehydrogenase (MCAD). This
high frequency, along with the fact that the resulting
disorder, MCAD deficiency, is treatable with a simple
dietary regimen, makes this disease a good candidate for
a newborn-screening program, and these screens, which
look for abnormal acylcarnitine levels in blood spots,
are now used worldwide. The goal of this study by An-
dresen et al. was to evaluate the tandem mass-spectrom-
etry method used in the newborn-screening programs.
They gathered a sample of 1900,000 blood spots from
the United States, on the basis of which they identified
62 newborns with abnormal acylcarnitine levels. Many
(63%) of the newborns identified in the screen were
homozygous for the 985ArG mutation, and another
34% were heterozygous for the mutation. Seven of these
heterozygotes also had a 199TrC mutation, a mutation
that had not been previously identified. A discrepancy
between the frequency of 985ArG alleles identified
through screening of newborns and the frequency of this
allele in people identified clinically has been thought to
result from false positives in the screen. Instead, this
discrepancy could be explained by the identification of
199TrC because it is as a relatively common mutation,
it is associated with abnormal acylcarnitine levels, and
it has not been found in clinically affected patients.
LD and Genotyping Errors, by Akey et al. (p. 1447)
Although linkage disequilibrium (LD) has been used ex-
tensively in gene mapping and evolutionary genetics
studies, the effects that genotyping errors have on gen-
eral measurements of LD have not been systematically
characterized. Akey et al. have more precisely calculated
these effects and have discovered that even a small ge-
notyping error rate for single-nucleotide polymorphisms
can have significant effects on measurements of LD, par-
ticularly if the frequency of the minor allele is low. These
studies were performed with both a stochastic-error
model, in which there is an equal probability that the
alleles at a locus will be genotyped incorrectly, and a
directed-error model, in which there is a systematic ge-
notyping error for a particular allele at a locus. The
differences between these models tend to diverge as the
minor-allele frequency increases. Akey et al. also com-
pared the effects that genotyping errors have on four
different measures of LD: D′, r, Q, and d. When error
rates are low, these measures do not differ substantially;
however, as the error rate increases, the differences be-
come more apparent. The measures Q and d were, in
general, more robust to error than were D′ and r, but,
overall, the choice of LD measure was also affected by
the allele and haplotype frequencies and by the error
model. Thus, no one LD measure was found to be su-
perior, in every situation, to the others.
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